Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA approves Avycaz for hospital-acquired and ventilator-associated bacterial pneumonias

Feb. 2, 2018

Vical enters collaboration to advance candidate for invasive aspergillosis

Feb. 2, 2018

UCB announces launch of Syndesi Therapeutics to develop therapeutics for cognitive disorders

Feb. 2, 2018

Phase II data on RX-3117 shows promise for pancreatic cancer treatment

Feb. 2, 2018

Avelumab shows clinical activity in patients with previously treated mesothelioma

Feb. 2, 2018

Daiichi Sankyo reviews highlights of third quarter of fiscal 2017

Feb. 2, 2018

Starpharma receives approval to initiate phase I/II study of DEP cabazitaxel

Feb. 2, 2018

FDA awards rare pediatric disease designation to MeiraGTx's A-002

Feb. 2, 2018

PharmAbcine, MSD to evaluate TTAC-0001 with Keytruda

Feb. 2, 2018

Pfizer enrolling patients in phase II study of PF-06823859 in moderate to severe dermatomyositis

Feb. 2, 2018

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 14, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 14, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...